Search results
Results From The WOW.Com Content Network
Study 3014 was a key clinical trial of approximately 24,000 patients which Sanofi-Aventis submitted to the FDA to seek approval for Ketek. The doctor who treated the most patients in Study 3014 (about 400), Maria "Anne" Kirkman Campbell, served a 57-month sentence in federal prison after pleading guilty to mail fraud, by defrauding Aventis and ...
2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi Pasteur. 2008: Sanofi Pasteur acquires Acambis plc, a biotech company.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Paul Hudson (born 14 October 1967) [2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [ 3 ] Early life
Corporate America can't seem to lay off workers fast enough. U.S. employers have already axed north of 100,000 jobs this year according to the latest figures from data firm Challenger, Gray ...
A platform match. The investment from Sanofi, a small fraction of the company's $46.2 billion annual revenue in 2023, is not so significant. But Sanofi is one of the world's largest vaccine makers ...
In November 2015, Sanofi announced its 2020 Strategic Plan that implies reshaping its activities into 3 portfolios: Diabetes, cardiovascular, and vaccines. [11] In May 2016, Olivier Brandicourt announced a reshuffle in the company's management, in line with the 2020 Strategic Plan. [12]